Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study-Reference-Cited by-同舟云学术

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Published:2017-08 Issue:8 Volume:18 Page:1076-1088
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Chiappella Annalisa,Martelli Maurizio,Angelucci Emanuele,Brusamolino Ercole,Evangelista Andrea,Carella Angelo Michele,Stelitano Caterina,Rossi Giuseppe,Balzarotti Monica,Merli Francesco,Gaidano Gianluca,Pavone Vincenzo,Rigacci Luigi,Zaja Francesco,D'Arco Alfonso,Cascavilla Nicola,Russo Eleonora,Castellino Alessia,Gotti Manuel,Congiu Angela Giovanna,Cabras Maria Giuseppina,Tucci Alessandra,Agostinelli Claudio,Ciccone Giovannino,Pileri Stefano A,Vitolo Umberto

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

3. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era;Ziepert;J Clin Oncol,2010

4. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis;Greb;Cancer Treat Rev,2007

5. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic Population;2024-09-11

2. Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma;Annals of Hematology;2024-09-02

3. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years;Blood Cancer Journal;2024-07-05

4. The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma;Journal of Personalized Medicine;2024-06-21

5. Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 ⁺ diffuse large-B cell lymphoma;Journal of Chemotherapy;2024-04-23